Payment overview · 2025
General Payments
$195.50
12 reported records · 7 companies
Healthcare provider profile · identity verified
Darrell A Bunch, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LONGVIEW, TX · NPI 1710974811
Verified facts
What the public records show
CMS Open Payments records show Darrell A Bunch, D.O. received $195.50 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.93 | 42.9% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.89 | 21.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.17 | 9.8% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $14.07 | 7.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $13.82 | 7.1% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $12.67 | 6.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $8.95 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $195.50 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $67.30 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.89 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $12.67 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $8.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
37 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 603 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 485 | 123 |
| Furosemide | Furosemide | 469 | 104 |
| Gabapentin | Gabapentin | 463 | 111 |
| Alprazolam | Alprazolam | 432 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 424 | 116 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 410 | 53 |
| Potassium Chloride | Potassium Chloride | 395 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 90 |
| Losartan Potassium | Losartan Potassium | 290 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 282 | 67 |
| Lisinopril | Lisinopril | 255 | 73 |
| Metformin Hcl | Metformin Hcl | 245 | 77 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 244 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 85 |
| Mirtazapine | Mirtazapine | 227 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 214 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 54 |
| Eliquis | Apixaban | 196 | 33 |
| Omeprazole | Omeprazole | 196 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 193 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 65 |
| Amitriptyline Hcl | Amitriptyline Hcl | 177 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 47 |
| Tramadol Hcl | Tramadol Hcl | 166 | 49 |
| Clonazepam | Clonazepam | 162 | 32 |
| Allopurinol | Allopurinol | 161 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 26 |
| Carvedilol | Carvedilol | 134 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 134 | 30 |
| Divalproex Sodium | Divalproex Sodium | 131 | 29 |
| Prednisone | Prednisone | 127 | 59 |
| Trazodone Hcl | Trazodone Hcl | 120 | 27 |
| Buspirone Hcl | Buspirone Hcl | 119 | 17 |
| Azelastine Hcl | Azelastine Hcl | 117 | 64 |
| Glimepiride | Glimepiride | 115 | 25 |
| Famotidine | Famotidine | 114 | 26 |
| Sertraline Hcl | Sertraline Hcl | 110 | 28 |
| Montelukast Sodium | Montelukast Sodium | 109 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 109 | 77 |
| Nifedipine Er | Nifedipine | 106 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 31 |
| Lorazepam | Lorazepam | 93 | 19 |
| Venlafaxine Hcl | Venlafaxine Hcl | 90 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 32 |
| Clonidine Hcl | Clonidine Hcl | 89 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 14 |
| Azithromycin | Azithromycin | 82 | 69 |
| Januvia | Sitagliptin Phosphate | 77 | 13 |
| Pregabalin | Pregabalin | 77 | 15 |
| Farxiga | Dapagliflozin Propanediol | 76 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 25 |
| Meloxicam | Meloxicam | 75 | 30 |
| Simvastatin | Simvastatin | 73 | 20 |
| Doxepin Hcl | Doxepin Hcl | 72 | 14 |
| Cefuroxime | Cefuroxime Axetil | 71 | 59 |
| Donepezil Hcl | Donepezil Hcl | 71 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 59 | suppressed |
| Levetiracetam | Levetiracetam | 59 | 11 |
| Estradiol | Estradiol | 58 | 19 |
| Finasteride | Finasteride | 57 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 13 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 19 |
| Atenolol | Atenolol | 48 | suppressed |
| Spironolactone | Spironolactone | 46 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 12 |
| Sucralfate | Sucralfate | 45 | 13 |
| Glipizide | Glipizide | 44 | 15 |
| Metformin Hcl Er | Metformin Hcl | 44 | 13 |
| Novolin N | Insulin Nph Human Isophane | 44 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 44 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Cephalexin | Cephalexin | 42 | 23 |
| Risperidone | Risperidone | 42 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Fluconazole | Fluconazole | 40 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 32 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Torsemide | Torsemide | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 19 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Ibuprofen | Ibuprofen | 26 | 12 |
| Jardiance | Empagliflozin | 26 | 12 |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 16 |
| Belsomra | Suvorexant | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | 13 |
| Topiramate | Topiramate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
| Zetia | Ezetimibe | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $195.50 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, JOURNAVX, TRELEGY ELLIPTA, WatchPATONE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error